Enhance Biotech Announces That Its Developments In Fertility Are Demonstrating Wider Commercial Opportunities Than Expected

NEW YORK, Nov. 12 /PRNewswire-FirstCall/ -- Enhance Biotech Inc. (BULLETIN BOARD: EBOI) today announced that its ongoing development program in male fertility is proving more fruitful than expected.

The Lif 316 family of compounds initially developed by Enhance for use in in-vitro fertilization (IVF) is demonstrating new and exciting opportunities available to the Company. This area of science has the advantage of enabling development to be conducted in a laboratory setting with live sperm samples of various origins, both human and mammalian. Enhance's laboratory work with both human and mammalian sperm has demonstrated results showing that applications can be developed in three key areas of fertility enhancement. The Company is now developing products and application strategies in three closely linked key areas:

  -- Enhancing or delaying activation of sperm in IVF
  -- Enhancing viability of stored/frozen sperm
  -- Enhancing sperm longevity

Chief Science Officer, Sam McCormick said, "The development teams are very excited by the significance of these findings as they are at the very heart of fertility issues. This has become an increasing problem area as both sperm quality and yield levels fall in human and mammalian fertilization statistics. This area of science provides us with the opportunity of increased control over, and enhanced quality of, sperm in the artificial fertilization processes."

Chris Every, CEO of Enhance also stated, "This technology opens up several new potential commercial opportunities for the Company. Although we have primarily focused upon human conditions, we now see a very real opportunity to commercialize the Lif 316 family of products in the veterinary artificial insemination area, where many millions of bovine, swine and equine fertilizations are carried out annually and where yield improvements would be considered very attractive to the industry."

Further announcements about specific aspects of the developments are expected as the Company reaches appropriate points in the development program over coming months; one of the first being the start of field trials in mammals for that part of the Lif 316 family focused upon enhancing sperm viability and longevity.

About Enhance Biotech

Enhance Biotech Inc. is a Holding company for its wholly owned subsidiary Enhance Lifesciences Inc. The product portfolio focuses upon two key areas of lifestyle drug development; sexual dysfunction conditions and dermatological products. Within those areas the key conditions are; sexual dysfunctions, including Premature Ejaculation and Male Fertility and dermatological, including Cellulite, Anti-aging and Skin Disorders covering Atopic Dermatitis and Psoriasis. Enhance's products are each licensed in at pre-clinical or Phase I stages and will be taken on through development and approval to market, adding significant value to each in the immediate future. This creates a valuable product pipeline portfolio in a market forecast to grow to US$29 billion by 2007. The pharmaceutical industry has invested over $20 billion in R&D for lifestyle drugs in the last ten years, although relatively few new products have as yet reached the market. Enhance Lifescience's lead development products fill an unmet need in a global blockbuster market. The Management and Science Team have a proven track record of successful development and commercialization of new products and the licensing out of valuable intellectual property. For more information on the Company please see the Company's website at http://www.enhancelifesciences.com/

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Enhance Biotech's compounds under development in particular; the potential failure of Enhance Biotech's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhance Biotech's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhance Biotech's business, structure or projections; the development of competing products; uncertainties related to Enhance Biotech's dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under the Company's prior name Becor Communications, Inc. The Company and Enhance Biotech disclaim any obligation to update these forward- looking statements.

CONTACT: Stuart Fine, Carpe DM, Inc., +1-908-490-0075, for EnhanceBiotech Inc.